Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation H Huang, H Weng, W Sun, X Qin, H Shi, H Wu, BS Zhao, A Mesquita, ... Nature cell biology 20 (3), 285-295, 2018 | 1956 | 2018 |
FTO plays an oncogenic role in acute myeloid leukemia as a N6-methyladenosine RNA demethylase Z Li, H Weng, R Su, X Weng, Z Zuo, C Li, H Huang, S Nachtergaele, ... Cancer cell 31 (1), 127-141, 2017 | 1258 | 2017 |
R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling R Su, L Dong, C Li, S Nachtergaele, M Wunderlich, Y Qing, X Deng, ... Cell 172 (1), 90-105. e23, 2018 | 855 | 2018 |
METTL14 inhibits hematopoietic stem/progenitor differentiation and promotes leukemogenesis via mRNA m6A modification H Weng, H Huang, H Wu, X Qin, BS Zhao, L Dong, H Shi, J Skibbe, ... Cell stem cell 22 (2), 191-205. e9, 2018 | 820 | 2018 |
m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer H Huang, H Weng, J Chen Cancer cell 37 (3), 270-288, 2020 | 769 | 2020 |
RNA N6-methyladenosine modification in cancers: current status and perspectives X Deng, R Su, H Weng, H Huang, Z Li, J Chen Cell research 28 (5), 507-517, 2018 | 597 | 2018 |
Histone H3 trimethylation at lysine 36 guides m 6 A RNA modification co-transcriptionally H Huang, H Weng, K Zhou, T Wu, BS Zhao, M Sun, Z Chen, X Deng, ... Nature 567 (7748), 414-419, 2019 | 495 | 2019 |
Targeting FTO suppresses cancer stem cell maintenance and immune evasion R Su, L Dong, Y Li, M Gao, L Han, M Wunderlich, X Deng, H Li, Y Huang, ... Cancer cell 38 (1), 79-96. e11, 2020 | 444 | 2020 |
Roles of METTL3 in cancer: mechanisms and therapeutic targeting C Zeng, W Huang, Y Li, H Weng Journal of hematology & oncology 13 (1), 117, 2020 | 305 | 2020 |
RNA demethylase ALKBH5 selectively promotes tumorigenesis and cancer stem cell self-renewal in acute myeloid leukemia C Shen, Y Sheng, AC Zhu, S Robinson, X Jiang, L Dong, H Chen, R Su, ... Cell stem cell 27 (1), 64-80. e9, 2020 | 272 | 2020 |
The biogenesis and precise control of RNA m6A methylation H Huang, H Weng, J Chen Trends in Genetics 36 (1), 44-52, 2020 | 210 | 2020 |
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia X Jiang, C Hu, S Arnovitz, J Bugno, M Yu, Z Zuo, P Chen, H Huang, ... Nature communications 7 (1), 11452, 2016 | 139 | 2016 |
Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis HL Huang, HY Weng, LQ Wang, CH Yu, QJ Huang, PP Zhao, JZ Wen, ... Molecular cancer therapeutics 11 (5), 1155-1165, 2012 | 104 | 2012 |
Attacking c-Myc: targeted and combined therapies for cancer H Huang, H Weng, H Zhou, L Qu Current pharmaceutical design 20 (42), 6543-6554, 2014 | 86 | 2014 |
Overexpression and knockout of miR-126 both promote leukemogenesis Z Li, P Chen, R Su, Y Li, C Hu, Y Wang, S Arnovitz, M He, S Gurbuxani, ... Blood, The Journal of the American Society of Hematology 126 (17), 2005-2015, 2015 | 82 | 2015 |
Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S H Weng, H Huang, B Dong, P Zhao, H Zhou, L Qu Cancer research 74 (16), 4409-4419, 2014 | 78 | 2014 |
PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease Z Li, P Chen, R Su, C Hu, Y Li, AG Elkahloun, Z Zuo, S Gurbuxani, ... Cancer research 76 (3), 619-629, 2016 | 77 | 2016 |
The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia H Weng, F Huang, Z Yu, Z Chen, E Prince, Y Kang, K Zhou, W Li, J Hu, ... Cancer Cell 40 (12), 1566-1582. e10, 2022 | 71 | 2022 |
RNA modifications in cancer: functions, mechanisms, and therapeutic implications H Huang, H Weng, X Deng, J Chen Annual Review of Cancer Biology 4, 221-240, 2020 | 70 | 2020 |
The pathological role and prognostic impact of miR-181 in acute myeloid leukemia H Weng, K Lal, FF Yang, J Chen Cancer genetics 208 (5), 225-229, 2015 | 69 | 2015 |